Inclusion Criteria:

          -  Histologically confirmed, localized prostate adenocarcinoma patients who are planning
             to have a radical prostatectomy.

          -  Diagnostic prostate biopsy must have been obtained within 6 months patients who had
             biopsies at outside facilities may be eligible if tissue availability and adequacy can
             be confirmed by pathology.

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Platelet >= 75,000/uL.

          -  Hemoglobin >= 9 g/dL.

          -  Hematocrit >= 27%.

          -  Absolute neutrophil count (ANC) >= 1500/uL.

          -  Creatinine < institutional upper limit of normal (ULN) OR creatinine clearance >= 50
             mL/min for patients with creatinine levels greater than ULN.

          -  Total bilirubin =< 1.5 X institutional ULN.

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 X
             institutional ULN.

          -  Serum amylase and lipase =< 1.5 X institutional ULN.

          -  Negative hepatitis panel for patients with a history of Hepatitis

          -  Participant must understand the investigational nature of this study and sign an
             Independent Ethics Committee/Institutional Review Board approved written informed
             consent form prior to receiving any study related procedure.

        Exclusion Criteria:

          -  Patients currently treated with systemic immunosuppressive agents, including steroids,
             are ineligible until 3 weeks after removal from immunosuppressive treatment.

          -  Patients who received hormonal therapy, 5-alpha reductase inhibitors (such as
             finasteride, dutasteride), chemotherapy, radiotherapy, major surgery, or biologic
             therapy within 3 weeks of protocol treatment.

          -  Patients with active prostatitis.

          -  Patients with active autoimmune disease or history of transplantation.

          -  Patients with comorbid medical conditions that render them unfit for surgery.

          -  Metastatic disease based on preoperative imaging.

          -  Cardiac risk factors including:

               -  Patients experiencing cardiac event(s) (acute coronary syndrome, myocardial
                  infarction, or ischemia) within 3 months of signing consent

               -  Patients with a New York Heart Association classification of III or IV.

          -  History of upper and lower gastrointestinal ulceration, upper gastrointestinal
             bleeding, or perforation within the past 3 years.

          -  History of bleeding disorders, known lesions at risk for bleeding, or history of
             recent clinically significant bleed or hemorrhage (<3months).

          -  Prior allergic reaction or hypersensitivity to aspirin, or other nonsteroidal
             antiinflammatory drugs (NSAIDs).

          -  Patients are ineligible if they plan on use of other NSAIDs at any dose during the
             trial. Patients who agree to stop regular NSAIDs are eligible and no wash out period
             is required.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Unwilling or unable to follow protocol requirements.

          -  Any condition which in the investigator?s opinion deems the participant an unsuitable
             candidate to receive study drug.